top of page

業績(2024年)

Publications
  1. Narita H, Kuroiwa K, Kawaguchi Y, Murai S, Sasaki Y, Homma M, Kawamata N, Hayashi H, Nagao K, Okamura R, Uesugi Y, Sasaki Y, Shimada S, Watanuki M, Arai N, Yanagisawa K, Shiozawa E, Yamochi T, Hattori N. High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma. Int. J. Mol. Sci. 2024, 25(20), 11057.

  2. Arai N, Narita H, Kuroiwa K, Nagao K, Hayashi H, Kawamata N, Okamura R, Sasaki Y, Shimada S, Watanuki M, Kawaguchi Y, Yanagisawa K, Hattori N. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation. Transplant Proc. 2024;56(8):1828-1835.

  3. Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, Ozaki R, Yoneyama K, Mizuno N, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Seki Y, Nogami K. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thromb Haemost. 2024 Aug 12. doi: 10.1055/a-2384-3585.

  4. Yoshizaki C, Yoshida Y, Nohmi S, Go Y, Kusakado R, Kawamura S, Inoue D, Kabasawa N, Yamaguchi F. EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report. Lung Cancer. 2024; 194: 107869.

  5. Ido K, Nakamae H, Hattori N, Kanaya M, Morita K, Hino M, Ohigashi H, Fukuda T, Eto T, Nagafuji K, Hiramoto N, Maruyama Y, Ota S, Matsuoka KI, Ando T, Akasaka T, Mori Y, Kamimura T, Kawakita T, Kawamura K, Kanda J, Onizuka M, Atsuta Y, Murata M. Effect of peptide-binding motif on survival of HLA-haploidentical transplantation with post-transplant cyclophosphamide. Br J Haematol. 2024 Jul 7. doi: 10.1111/bjh.19630.

  6. Sasaki Y, Murai S, Hayashi H, Kawamata N, Nagao K, Kuroiwa K, Narita H, Okamura R, Shimada S, Watanuki M, Arai N, Kawaguchi Y, Yanagisawa K, Shiozawa E, Yamochi T, Hattori N. Clinicopathological differences in MYC and BCL2 protein expression between primary extranodal and nodal diffuse large B-cell lymphoma. Pathol Res Pract. 2024; 260: 155425.

  7. Uesugi Y, Ikeda D, Fukumoto A, Tabata R, Miura D, Narita K, Takeuchi M, Matsue K. Use of the Second Revision of the International Staging System for prognostic stratification of multiple myeloma patients in real-world clinical practice and the importance of sub-groups, including age. Haematologica. 2024; 109(5): 1593-1597.

  8. Arai S, Tachibana T, Izumi A, Takeda T, Tamai Y, Sato S, Hashimoto C, Fujimaki K, Ishii R, Kabasawa N, Hirasawa A, Inoue Y, Tanaka M, Suzuki T, Nakajima H. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Int J Hematol. 2024;120(3): 337-346.

  9. Baba Y, Hida N, Sambe T, Abe M, Kabasawa N, Sakai H, Yoshimura K, Fukuda T. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience. Anticancer Res. 2024; 44(5): 2003-2007.

  10. Miyazaki T, Tachibana T, Suzuki T, Izumi A, Fujimaki K, Sato S, Tamai Y, Michishita Y, Suzuki T, Ishii R, Hirasawa A, Hashimoto C, Kabasawa N, Inoue Y, Ishiyama T, Yamamoto K, Kanamori H, Tanaka M, Nakajima H. Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio. Transplant Cell Ther. 2024; 30(4): 400.e1-400.e9.

  11. Kuroiwa K, Sato M, Narita H, Okamura R, Uesugi Y, Sasaki Y, Shimada S, Watanuki M, Fujiwara S, Kawaguchi Y, Arai N, Yanagisawa K, Iezumi K, Hattori N. Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2024; 119(5): 583-591.

  12. Sasaki Y, Murai S, Shiozawa E, Yamochi T, Hattori N. Blastic Plasmacytoid Dendritic Cell Neoplasm in Long-Term Complete Remission After Venetoclax Monotherapy. Cureus. 2024; 16(1): e52446.

  13. Shimada S, Kuroiwa K, Narita H, Okamura R, Uesugi Y, Sasaki Y, Watanuki M, Arai N, Kawaguchi Y, Fujiwara S, Yanagisawa K, Hattori N. Acquired thrombotic thrombocytopenic purpura during durvalumab monotherapy for non-small cell lung cancer. Rinsho Ketsueki. 2024;65(1):24-29. Japanese.

bottom of page